MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change.
Xu
Hongxia
H
Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Zhang
Zhuo
Z
Li
Mao
M
Zhang
Ruiwen
R
D017209:Apoptosis; D002453:Cell Cycle; D045744:Cell Line, Tumor; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000378:metabolism; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D011487:Protein Conformation; D025941:Protein Interaction Mapping; D017434:Protein Structure, Tertiary; D051736:Proto-Oncogene Proteins c-mdm2 / Q000378:metabolism*; D015398:Signal Transduction; D025801:Ubiquitin / Q000737:chemistry
D050759:Cyclin-Dependent Kinase Inhibitor p21; D025801:Ubiquitin; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D005982:Glutathione Transferase; D046988:Proteasome Endopeptidase Complex